---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000067"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:43:54.388339+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine settles INGREZZA patent litigation; generic entry delayed to 2040

## Summary
- Settlement with Sandoz and Crystal grants generic INGREZZA license starting Feb 1, 2040, or earlier under certain conditions.
- Patent litigation resolved for one ANDA filer; two other ANDA challenges remain pending with trial set for Jan 2, 2024.
- Agreement to be submitted to FTC and DOJ as required by law.
- INGREZZA is Neurocrine's drug for tardive dyskinesia and Huntington's chorea.

## SEC filing metadata
- accession: 0000914475-23-000067
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/0000914475-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000067/nbix-20231005.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000067
- JSON: https://secwatch.observer/filing/0000914475-23-000067.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.